FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
OC-04 | The chronopharmacology of atogepant in migraine prevention: a real-world evaluation of influence of timing of administration on effectiveness and tolerability Luigi Francesco Iannone,1,2 Gabriele Sebastianelli,3 Flavia Lo Castro,2 Federico De Santis,4 Michele Corrado,5 Marilena Marcosano,6,7 Raffaele Ornello,4 Licia Grazzi,8 Danilo Antonio Montisano,8 Francesco De Cesaris,9 Antonio Munafò,9 Gianluca Avino,10 Michele Trimboli,11 Maria Albanese,12 Antonio Russo,13 Giorgio Dalla Volta,14 Marina Romozzi,15 Paola Merlo,16 Luisa Fofi,6,7 Alberto Doretti,17 Gloria Vaghi,5 Francesca Pistoia,4 Delfina Ferrandi,18 Stefania Battistini,19 Gianluca Coppola,3 Simona Sacco,4 Simona Guerzoni,2 Claudia Altamura,6,7 Fabrizio Vernieri,6,7 On behalf of the Italian Headache Registry (RICe) Study Group | 1Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia; 2Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena; 3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina; 4Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 5Department of Brain and Behavioral Sciences, University of Pavia; Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 6Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma; 7Neurology Unit, Università Campus Bio-Medico di Roma; 8Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; 9Headache center and Clinical Pharmacology, AOU Careggi, Florence; 10SOC Neurologia, Ospedale di Prato; 11Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 12Università Roma Tor Vergata, Roma; 13Università della Campania "Luigi Vanvitelli", Napoli; 14U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 15Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 16UO di Neurologia, Humanitas Gavazzeni, Bergamo; 17Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano; 18Neurology Department, Azienda Ospedaliero Universitaria, Santi Antonio e Biagio e Cesare Arrigo, Alessandria; 19Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy
187 -
PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study Alberto Doretti,1 Anna Ambrosini,2 Simone Braca,3 Florindo D’Onofrio,4 Elisa Maria Piella,5 Pinar Kokturk,6 Rosario Iannacchero7 | 1Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; 2Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; 3Headache Centre, University of Naples “Federico II”, Naples, Italy; 4UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; 5Neurosciences Department, University of Turin, Turin, Italy; 6Teva Netherlands B.V., Haarlem, The Netherlands; 7Department of Neurology, Headache Center, Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy
162 -
OC-05 | Mid-term effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study) Fabrizio Vernieri,1 Luigi Francesco Iannone,2,3 Gabriele Sebastianelli,4 Flavia Lo Castro,2, Federico De Santis,5 Michele Corrado,6 Marilena Marcosano,1 Raffaele Ornello,5 Licia Grazzi,7 Danilo Antonio Montisano,7 Francesco De Cesaris,8 Antonio Munafò,8 Gianluca Avino,9 Michele Trimboli,10 Maria Albanese,11 Antonio Russo,12 Giorgio Dalla Volta,13 Marina Romozzi,14 Paola Merlo,15 Maria Pia Prudenzano,16 Maria Rosaria Valente,17 Innocenzo Rainero,18 Giada Giuliani,19 Luisa Fofi,1 Alberto Doretti,20 Gloria Vaghi,6 Francesca Pistoia,5 Delfina Ferrandi,21 Stefania Battistini,22 Simona Sacco,5 Simona Guerzoni,2 Claudia Altamura1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Fondazione Policlinico Campus Bio-Medico, Roma; 2AOU Policlinico di Modena; 3Università di Modena e Reggio Emilia. 4Sapienza University of Rome Polo Pontino, Latina; 5University of L’Aquila; 6University of Pavia, Pavia, Italy and IRCCS Mondino Foundation, Pavia; 7IRCCS Istituto Neurologico Carlo Besta, Milano; 8AOU Careggi, Firenze; 9SOC Neurologia, Ospedale di Prato, Prato; 10Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 11Università Roma Tor Vergata, Roma; 12Università della Campania "Luigi Vanvitelli", Napoli; 13U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 14Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma; 15UO di Neurologia, Humanitas Gavazzeni, Bergamo; 16Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari; 17Dipartimento di Neuroscienze, Azienda Sanitaria Universitaria Integrata di Udine; 18Dipartimento di Neuroscienze, Città della Salute e della Scienza di Torino; 19Centro per la diagnosi e terapia delle cefalee, Policlinico Umberto I, Roma; 20IRCCS Istituto Auxologico Italiano, Milano; 21AOU Alessandria; 22University of Siena, Siena, Italy
285 -
PO-12 | The long-term efficacy on migraine of non-ketogenic low-carb diet after treatment with ketogenic diet Silvia Favaretto,1 Francesco Francini Pesenti2 | 1Headache centre, Neurology Unit, Department of Neuroscience, University Hospital of Padua; 2Department of Medicine (DIMED), Clinical Nutrition, University Hospital of Padua, Italy
528 -
PO-09 | When migraine turns severe: a case of aura that lasts too long Alessandra Fera,1 Erica Agosto,1 Giulia Grasso,2 Cristina Vassia,2 Francesca Feyles,2 Carlotta Canavese,3 Sara Racalbuto,2 Antonia Versace2 | 1Department of Public Health and Pediatrics, University of Turin; 2Department of Pediatric Emergency, Pediatric Headache Centre, Regina Margherita Children’s Hospital, Turin; 3Department of Child Pathology and Care “Regina Margherita”, SSD Pediatric Neurology, Regina Margherita Children’s Hospital, Turin, Italy
389 -
OC-19 | A multicenter, retrospective case series of trigeminal autonomic cephalalgias in children and adolescents Alessandro Borrelli,1 Vittorio Sciruicchio,2 Alessandro Ferretti,3 Irene Toldo,4 Antonia Versace,5 Elisabetta Tozzi,6 Agnese Onofri,7 Giorgia Sforza,1 Gabriele Monte,1 Fabiana Ursitti,1 Massimiliano Valeriani,1,8,9 Laura Papetti1 | 1Developmental Neurology Unit, IRCCS Bambino Gesù Children's Hospital, Rome; 2Children Epilepsy and EEG Center, San Paolo Hospital, ASL Bari;3Department of Neuroscience, Mental Health & Sense Organs (NESMOS), Faculty of Medicine & Psychology, Sant'Andrea Hospital, Rome; 4Pediatric Neurology and Neurophysiology Unit, Department of Woman's and Child Health, University of Padua; 5A.O.U. Città della Salute e della Scienza di Torino, Department of Pediatric Emergency, Regina Margherita Children's Hospital, Turin; 6Department of Clinical Medicine, Public Health, Life and Environmental Sciences, L'Aquila; 7Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; 8Tor Vergata University of Rome, Systems Medicine Department, Rome, Italy; 9Aalborg University, Center for Sensory-Motor Interaction, Aalborg, Denmark
117 -
PO-41 | Eptinezumab for difficult-to-treat migraine: who responds and who needs more Alessandro Visentini,1,2,3 Roberta Messina,1,2,3 Ilaria Cetta,1,2,3 Edorardo Ratto,1 Laura Zanandrea,1,3 Federica Genovese,1,2,3 Irene Chinali,1 Bruno Colombo,1 Massimo Filippi1,2,3 | 1Neurology Unit and 2Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 3Vita-Salute San Raffaele University, Milan, Italy
288 -
PO-92 QZU® (Kudzu e.s.: 200 mg of which Isoflavones: 80 mg and Puerarin: 60 mg; ComplexZyme vegan®: 40 mg) in the prophylaxys of migraine without aura: a retrospective observational study Ennio Pucci,1 Ludovica Pucci,2 Alberto Vercesi3 | 1Department of Nervous System and Behavioral Sciences, University of Pavia; 2Nutritional biologist, Master in Nutritional and Clinical Dietetics, University of Pavia, Italy; 3Scientific Advisor
642 -
PO-39 | Leeds Dependence Questionnaire (LDQ) in migraine: diagnostic utility without predictive value for anti-CGRP (R) response Antonio Munafò,1 Andrea Burgalassi,1 Giulia Vigani,2 Francesco De Cesaris,1 Alberto Chiarugi1,2 | 1Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy; 2Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
252 -
PO-79 | Survey on adherence and tolerability of atogepant used as migraine preventive treatment D.A. Montisano,1 G. Vaghi,2,3 A. Paris,1 R. De Icco,2,3 B. Agostini,2,3 M. Giraudo,2,3 A. Solfrizzi,2,3 C. Tassorelli,2,3 G. Sances,3 L. Grazzi | 1Fondazione IRCCS C.Besta Istituto Neurologico, SSD Headache Center, Milan, Italy; 2University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy; 3IRCCS Mondino Foundation, Headache Science & Neurorehabilitation Unit, Pavia, Italy
260 -
PO-38 | Impact of atogepant on achieving best possible quality of life among patient global impression of change responders Cristina Tassorelli,1 Pranav Gandhi,2 Molly Duan,2 Karen Carr,2 Kandavadivu Umashankar,2 Jonathan Stokes,2 Grace Forde,3 Tanya Bilchik,4 Martina Martini*, Rashmi Halker Singh5 | 1University of Pavia, Pavia, Italy; 2AbbVie, North Chicago, IL, USA; 3North American Partners in Pain Management, North New Hyde Park, NY, USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy.
246 -
PO-69 | Three-month atogepant treatment modulates dopaminergic-related functional connectivity in episodic migraine Davide Fedeli,1 Danilo Antonio Montisano,1 Greta Demichelis,1 Giuseppe Ciullo,1,2 Jean Paul Medina Carrion,1 Maria Grazia Bruzzone,1 Emilio Ciusani,1 Alessandra Erbetta,1 Marina Grisoli,1 Erika Guastafierro,1 Domenico D’Amico,1 Alberto Raggi,1 Anna Nigri,1 Licia Grazzi1 | 1Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 2University of Parma, Parma, Italy
220 -
PO-35 | Treatment of chronic and episodic migraine with atogepant improves quality of life in patients with comorbid multiple sclerosis: the experience of the Headache Center at Spaziani Hospital, Frosinone Laura Borrello; Fabiana Marinelli; Maria Lorena Marziale; Ilaria Avallone; Fulvio Ferrante; Roberto De Simone | Neurology Unit, Headache Center, Multiple Sclerosis Center, UOC Pharmacy, Spaziani Hospital, Frosinone (FR), Italy
232 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
210 -
PO-52 | Long-term efficacy of CGRP mAbs: new insights and current evidence Oreste Marsico,1 Marta Lioi,2 Rosario Iannacchero,3 Michele Trimboli3 | 1Department of Neuroscience, “Giovanni Paolo II” Hospital, Lamezia Terme, Catanzaro, Italy; 2Department of Neurology, Magna Graecia University, Catanzaro, Italy; 3Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
161
1 - 16 of 16 items